Continuous Monitoring and Management of Vaginal Health Via Multifunctional OCT/OCTA/OCE Endoscopy

Sponsor
University of California, Irvine (Other)
Overall Status
Recruiting
CT.gov ID
NCT04737616
Collaborator
(none)
90
1
2
23.5
3.8

Study Details

Study Description

Brief Summary

We have recently developed and optimized a vaginal Optical Coherence tomography/angiography endoscopy imaging system. This technology is able to obtain a comprehensive image of the vaginal epithelium, blood vessels, and lamina propria. The primary focus of this study is establishing the Optical Coherence Tomography system's capability of capturing vaginal changes that occur before and after menopause, as well as before and after treatment with fractional-CO2 laser therapy.

There are two aims of this study.

Aim 1:
  1. To determine the feasibility and sensitivity of the integrated optical coherence endoscope to assess vaginal tissue integrity in pre, peri and postmenopausal women.
Aim 2:

To optically visualize the effects of fractional-CO2 laser treatment on vaginal tissue over the course of C02 vaginal laser therapy.

Condition or Disease Intervention/Treatment Phase
  • Device: CO2 laser
  • Device: OCT
N/A

Detailed Description

The vaginal Optical Coherence tomography/angiography endoscopy imaging system. This technology is able to obtain a comprehensive image of the vaginal epithelium, blood vessels, and lamina propria. The primary focus of this study is establishing the Optical Coherence Tomography system's capability of capturing vaginal changes that occur before and after menopause, as well as before and after treatment with fractional-CO2 laser therapy.

There are two aims of this study.

Aim 1: To determine the feasibility and sensitivity of the integrated optical coherence endoscope to assess vaginal tissue integrity in pre, peri and postmenopausal women

We will enroll up to 90 women (age: 18 and older) who will be classified as pre-menopausal, peri- menopausal, or post-menopausal. There will be 30 women in each group. All enrolled subjects will first complete informed consents.

They will then fill out a questionnaire (the vulvovaginal symptom questionnaire) about their vaginal health. This will be followed by a pelvic exam to determine the vaginal health (vaginal health index) and to obtain a vaginal swab for assessment of the vaginal microbiome .

This will be followed by OCT scan of the vaginal tissue. There will be only one visit.

Aim 2: To optically visualize the effects of fractional-CO2 laser treatment on vaginal tissue over the course of C02 vaginal laser therapy.

Up to thirty Post-menopausal subjects with GSM who desire fractional-CO2 laser therapy, will be recruited.

Each visit will include: completion of a questionnaire (the vulvovaginal symptom questionnaire) about their vaginal health; followed by a pelvic exam to determine the vaginal health (vaginal health index) and to obtain a vaginal swab for assessment of the vaginal microbiome and an OCT scan of the vaginal tissue before the CO2 vaginal laser treatment.

This group will have a total of three visits with CO2 laser treatments. There will be a fourth visit which will include all the above study procedures except the CO2 laser treatment.

Subjects who complete 3 laser treatments will be offered participation in long term follow up with repeat OCT imaging every 3 months at 3, 6, 9 and 12 months after the final laser treatment to study the long- term effects of the laser treatment on the vaginal tissue.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Continuous Monitoring and Management of Vaginal Health Via Multifunctional 1.7um Optical Coherence Tomography/Angiography Endoscopy
Actual Study Start Date :
Jul 16, 2020
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: CO2 Laser +OCT

Postmenopausal women with genitourinary syndrome of menopause who will receive CO2 vaginal laser treatment

Device: CO2 laser
Fractional CO2 vaginal laser for genitourinary syndrome of menopause

Device: OCT
Optical coherence tomography endoscope

Experimental: OCT only

Premenopausal, peri-menopausal and postmenopausal women who will only get one time OCT scan

Device: OCT
Optical coherence tomography endoscope

Outcome Measures

Primary Outcome Measures

  1. Vaginal epithelial thickness (VET) [2 years]

    Vaginal epithelium thickness measured with the OCT.

Secondary Outcome Measures

  1. blood vessel density [2 years]

    The blood vessel density will be measured by OCT

  2. Vaginal Health Index (VHI) [2 years]

    VHI to be measured on exam

  3. Lactobacillus abundance [2 years]

    Lactobacillus abundance by RNA sequencing

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes

Inclusion criteria

Aim 1:

. Women who are premenopausal, peri-menopausal and postmenopausal

Aim 2:

. Postmenopausal women with genitourinary syndrome of menopause

Exclusion criteria

  • history of pelvic irradiation

  • Current pregnant or breastfeeding

  • Use of hormone replacement therapy within three months of study enrollment

  • Inability to read and understand english

  • inability to follow research instructions

Contacts and Locations

Locations

Site City State Country Postal Code
1 UC Irvine Costa Mesa California United States 92626

Sponsors and Collaborators

  • University of California, Irvine

Investigators

  • Principal Investigator: Felicia Lane, MD, UC Irvine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Felicia Lane, Chair, division of FPMRS, University of California, Irvine
ClinicalTrials.gov Identifier:
NCT04737616
Other Study ID Numbers:
  • HS# 2019-5446
First Posted:
Feb 4, 2021
Last Update Posted:
Feb 4, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes

Study Results

No Results Posted as of Feb 4, 2021